Table 10 Expression levels of miRNAs targeting i.a. TYMS mRNA in cancer
From: MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy
miRNA | Level†| Cancers‡ | References |
|---|---|---|---|
miR-330-3p | Down | CRC tissues and HCT116, SW480 cell lines | Wang et al. (2022b) |
| Â | Down | CRC tissues: 5FU resistant vs sensitive (after surgery) | Gao et al. (2021a) |
| Â | Down | CRC tissues and SW480, SW620 cell lines | Huang et al. (2020b) |
| Â | Down | CRC tissues and HCT116, HT29, SW620, SW480 cell lines | Xu et al. (2017) |
| Â | Down | GC tissues and cell lines | Ma et al. (2020) |
| Â | Down | GC tissues and cell lines | Guan et al. (2016) |
| Â | Up | ESCC: two cell lines | Meng et al. (2015) |
| Â | Down | LSCC tissues and cell lines | Cheng et al. (2020a) |
| Â | Down | LSCC tissues and two cell lines | Fan and Zhu (2022) |
| Â | Down | OSCC tissues | Qian et al. (2021) |
| Â | Up | NSCLC tissues | Wang et al. (2021e) |
| Â | Up | NSCLC primary tissues with vs without brain metastasis | Wei et al. (2019b) |
| Â | Up | NSCLC tissues and four cell lines (i.a. A549) | Chen et al. (2019b) |
| Â | Up | NSCLC tissues | Liu et al. (2015) |
| Â | Up | BRCA tissues, four cell lines (i.a. MCF-7, MDA-MB-231) | Ji et al. (2021) |
|  | Up | BRCA tissues (ER/HER2 ±), metastatic vs non-metastatic | Zhang et al. (2019b) |
|  | Up | BRCA tissues (ER/PR ±) | Wang et al. (2018b) |
|  | Down | BRCA (TNBC) tissues (stage I–III) | He et al. (2020) |
| Â | Up | HCC tissues and four cell lines | Zhao et al. (2019b) |
|  | Up | HCC tissues, TNM stage II + III vs I, six cell lines | Hu et al. (2017a) |
| Â | Up | PDAC cell lines (i.a. PANC-1, SW 1990) | Xiong et al. (2019) |
|  | Down | OVCA tissues, stage III–IV vs I–II, three cell lines | Cai et al. (2021) |
| Â | Down | PCa tissues and four cell lines (i.a. PC-3, DU145) | Li et al. (2020b) |
| Â | Down | PCa: four cell lines (i.a. PC-3, DU145) | Lee et al. (2009) |